About Us

We help clients assess chemical compound safety to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products. At the frontline of next generation risk assessment (NGRA), we develop customized cell-based assays to determine safety, model chemical disposition in the body, and analyze and interpret genetic data. Our solutions save our clients time and money by bringing their products to market faster.

Latest News (See all)

Development of in vitro assays for point-of-contact inhalation toxicity should consider two factors: 1) the physiological relevance of the cell culture model, and 2) the route of exposure. Organotypic culture models may better replicate in vivo adverse outcomes and allow for repeat exposures, whereas simpler cell-line-based models may be more applicable to high-throughput acute testing. Exposure of submerged cultures to compounds in solution is a commonplace approach, compatible with many in vitro assays and amenable to scaling for high-throughput testing. However, exposure of cultures at the air-liquid interface may better simulate in vivo inhalation exposure to vapors…Read more »

Durham, N.C., USA March 23rd, 2020 — ScitoVation, a solution leader recognized as industry experts in cell-based assays and computational methods announced today the launch of a partnership with BioPredic International, a contract services, research and life sciences tools provider based in France. The partnership centers around the Biopredic-owned HepaRG® immortal liver cell line. ScitoVation will serve as a center of service excellence in the Americas for HepaRG® as BioPredic’s preferred CRO partner in the Americas providing contract services, product development and technical support to the market. Together the two companies will launch …Read more »

Featured Offering

ScitoVation and BioSpyder are excited to introduce our new transcriptomics analysis package, ScitoXpress™. ScitoXpress™ provides important information about points of departure (POD) and potential modes of action (MoA) for our clients’ compounds. ScitoXpress™ characterizes chemical risk cost-efficiently and rapidly.

Because changes in gene expression precede changes in phenotype, a robust transcriptomics package like ScitoXpress™ can provide answers at lower doses compared to disease or tumor endpoints are typical used in in vivo studies. ScitoXpress™ offers the additional advantages of:

  • Providing utility in guiding additional studies, resulting in cost- and time-savings
  • Being based on a rigorous scientific approach, applied by experts
  • Having the support of U.S. EPA

Learn more about ScitoXpress™ during our webinar on Thursday, April 4th. We look forward to sharing more with you!

Who We Serve

By combining modern biological and computational methods, we help our clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products.


To kick off a new year and decade, we assessed ScitoVation’s current and prospective positioning in the risk assessment community.  As part of that process, the leadership team reviewed our… Read more »

By Mel Andersen, Ph.D., Senior Program Advisor It’s a grand time to be a toxicologist committed to using non-animal based biological and computational methods to assess the safety of chemicals and chemical products for human populations.  My toxicology career… Read more »

Whether you are a client, prospective client, prospective employee, a partner or general member of the public, thank you for your interest in ScitoVation and for visiting our Internet site.… Read more »